Trisalus Life Sciences
Business Services · Colorado, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
6272 W 91st Ave, Westminster, Colorado, ...Phone Number
(888) 321-5212Website
www.trisaluslifesci.comRevenue
$44.9 MillionStock Symbol
TLSIIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About Trisalus Life Sciences
TriSalus Life Sciences is an emerging immuno-oncology company dedicated to developing immunotherapy treatments for liver and pancreatic tumors using novel delivery technologies to improve patient outcomes. TriSalus is pursuing multiple solid tumor indications with investigational SD-101 and is working to acquire other immuno-oncology agents to pair with its proprietary Pressure-Enabled Drug Delivery infusion system for the administration of therapeutics intravascularly into visceral organ solid tumors. In combination with checkpoint inhibitors, TriSalus' focus is to reprogram the dominant immunosuppressive cell population in liver and pancreatic tumors. This innovative approach in development has the potential to leverage multiple mechanisms that can work together with the goal of overcoming inherent immune suppression within the solid tumor microenvironment.Explore more
Trisalus Life Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Trisalus Life Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Trisalus Life Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Trisalus Life Sciences has new funding data
Congratulate Masked Content for being promoted to Masked Content at Trisalus Life Sciences
Check out if Trisalus Life Sciences is spiking on competitors!
Check if Trisalus Life Sciences has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Trisalus Life Sciences recently announced quarterly report
Click to see if Trisalus Life Sciences had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Trisalus Life Sciences launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Trisalus Life Sciences as Masked Content
Find more new buyers
Compare Similar Companies to Trisalus Life Sciences
Compare insights from companies similar to Trisalus Life Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Trisalus Life Sciences
$44.9M
51-200
Public
$122.6M
2009
RH
Robert HolburnVice President, Chief Financial Officer
Company Profile Activity
Activity Insights
Trisalus Life Sciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Trisalus Life Sciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Trisalus Life Sciences.
Trisalus Life Sciences financials insights
Gather financial insights about Trisalus Life Sciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Unspecified
$3.7M
Series A
$6.1M
2013
Unspecified
$16.4M
Series B
$18.2M
2015
Series C
$15M
2017
Series D
$12.9M
2020
Debt
$350K
2024
Debt
$50M
Trisalus Life Sciences Tech Stack
A closer look at the technologies used by Trisalus Life Sciences
Most Recent Scoops
Project
Trisalus Life Sciences has published the largest real-world evidence study of pressure-enabled drug delivery (PEDD) ever conducted, encompassing 603 PEDD patients matched against more than 16,210 non-PEDD patients drawn from a 300 million patient, population-based claims database covering 96% of US payers, with data spanning January 2020 through March 2024.
Project
Trisalus Life Sciences has two prospective clinical studies underway PRESSURE at Stanford, a randomized study of TriNav and TARE for liver metastases comparing tumor absorbed dose, response rate, and disease control to the current standard of care, and PREDICTT at MD Anderson, a prospective study evaluating PEDD impact in hypovascular tumors both designed to generate head-to-head data to drive clinical adoption at top academic centers.
Medical Research, Clinical Operations
Project
Trisalus Life Sciences is preparing to publish results from two completed investigator-initiated trials the PETER study at Massachusetts General Hospital and TRI590 at MD Anderson both of which have completed data analyses and are targeting publication submission in the current quarter, with the company anticipating these readouts will serve as a meaningful catalyst for second-half commercial momentum.
Medical Research
Pain Point
Trisalus Life Sciences is experiencing a regulatory delay in the FDA review of TriNav Advance, which is now running approximately five months past the 30-day MDUFA review goal. While the company still expects clearance in the second half of the year, the delay has removed anticipated advanced revenue from its H2 2026 forecast, and the company is taking a prudent approach to launch planning given the unpredictability of clearance timing.
Barriers
Person-Based
Healthcare Technology
Trisalus Life Sciences News & Media
TLSI (TLSI) Securities Fraud Investigation - Levi & Korsinsky
TriSalus Life Sciences Inc. reaffirmed $60-$62 million revenue guidance on March 5, 2026. Months later, the company cut that outlook to $54-$57 million after missing Q1 estimates. NEW YORK, May 22, 2026 /PRNewswire/ -- TriSalus Life Sciences Inc. (TLSI) shareholders lost value after the...TLSI Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of TLSI (TLSI)
TriSalus Life Sciences Inc. told investors it expected $60-$62 million in 2026 revenue. The company's own GAAP figures told a different story -- and months later, that outlook was slashed to $54-$57 million. NEW YORK, May 15, 2026 /PRNewswire/ -- Investors in TriSalus Life Sciences Inc....TriSalus Life Sciences, Inc. (TLSI) Q1 2026 Earnings Call Transcript
TriSalus Life Sciences, Inc. (TLSI) Q1 2026 Earnings Call May 12, 2026 4:30 PM EDTCompany ParticipantsMary Szela - CEO, President & DirectorDavid...TriSalus (TLSI) Initiates Patient Enrollment for PREDICTT Liver Tumor Clinical Trial
TriSalus Life Sciences Inc. (NASDAQ:TLSI) is one of the best fast growing penny stocks to buy right now. On May 4, TriSalus Life Sciences initiated patient enrollment for the PREDICTT clinical trial, a prospective study evaluating its proprietary Pressure-Enabled Drug Delivery/PEDD technology in patients with primary or metastatic liver tumors. Conducted at The University of […]
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Trisalus Life Sciences
Sign Up For FreeTo access detailed company insights
TriSalus Life Sciences is an emerging immuno-oncology company dedicated to developing immunotherapy treatments for liver and pancreatic tumors using novel delivery technologies to improve patient outcomes. TriSalus is pursuing multiple solid tumor indications with investigational SD-101 and is working to acquire other immuno-oncology agents to pair... Read More
